FDA Approves the Cannabis Based Drug Epidiolex to Treat TSC Seizures
source: pixabay.com

FDA Approves the Cannabis Based Drug Epidiolex to Treat TSC Seizures

As published by the Food and Drug Administration; The U.S. FDA has just approved the first FDA approved therapy derived from cannabis (Epidiolex, a CBD solution) to treat tuberous sclerosis…

Continue Reading FDA Approves the Cannabis Based Drug Epidiolex to Treat TSC Seizures
A Possible Treatment for CDKL5 Deficiency Disorder has Earned Rare Pediatric Disease Designation
source: pixabay.com

A Possible Treatment for CDKL5 Deficiency Disorder has Earned Rare Pediatric Disease Designation

According to a story from BioSpace, the pharmaceutical company Marinus Pharmaceuticals, Inc. announced recently that its investigational product candidate ganaxolone has earned Rare Pediatric Disease designation from the US Food…

Continue Reading A Possible Treatment for CDKL5 Deficiency Disorder has Earned Rare Pediatric Disease Designation
Tuberous Sclerosis Complex: CBD Oral Solution Epidiolex Approved to Treat Seizures
source: pixabay.com

Tuberous Sclerosis Complex: CBD Oral Solution Epidiolex Approved to Treat Seizures

According to a story from GlobeNewswire, the biopharmaceutical company GW Pharmaceuticals plc recently announced that its CBD oral solution Epidiolex® has recently been approved as a treatment for seizures associated…

Continue Reading Tuberous Sclerosis Complex: CBD Oral Solution Epidiolex Approved to Treat Seizures
Congenital Ichthyosis and Tuberous Sclerosis Complex Clinical Trials are Now Enrolling Patients
source: pixabay.com

Congenital Ichthyosis and Tuberous Sclerosis Complex Clinical Trials are Now Enrolling Patients

Timber Pharmaceuticals focuses on rare diseases of dermatologic origin. These include scleroderma, congenital ichthyosis, tuberous sclerosis complex, and facial angiofibromas. They are currently working on two clinical trials. Trial 1…

Continue Reading Congenital Ichthyosis and Tuberous Sclerosis Complex Clinical Trials are Now Enrolling Patients

Updates from Marinus on Ganaxolone Trials for 3 Forms of Epilepsy

Marinus Pharmaceuticals has recently announced updates on its ganaxolone programs for tuberous sclerosis complex (TSC), PCDH19-related epilepsy (PCDH19-RE), and CDKL5 deficiency disorder (CDD). Ganaxolone Ganaxolone is a positive allosteric modulator…

Continue Reading Updates from Marinus on Ganaxolone Trials for 3 Forms of Epilepsy
Ganaxolone Being Investigated as Treatment for Tuberous Sclerosis and CDKL5 Deficiency Disorder
source: pixabay.com

Ganaxolone Being Investigated as Treatment for Tuberous Sclerosis and CDKL5 Deficiency Disorder

Marinus Pharmaceuticals is a pharmaceutical company that works to create treatments for epilepsy and other neuropsychiatric disorders. They are in the process of conducting clinical trials to evaluate the safety…

Continue Reading Ganaxolone Being Investigated as Treatment for Tuberous Sclerosis and CDKL5 Deficiency Disorder
Positive Results at End of Phase 3 Trial of Candidate Tuberous Sclerosis Complex Drug – CBD
cbd123 / Pixabay

Positive Results at End of Phase 3 Trial of Candidate Tuberous Sclerosis Complex Drug – CBD

According to a press release from the British biotechnology company GW Pharmaceuticals, the company has reported successful results at the conclusion of its phase 3 trial of tuberous sclerosis complex…

Continue Reading Positive Results at End of Phase 3 Trial of Candidate Tuberous Sclerosis Complex Drug – CBD
Study Shows We Need Better Awareness of Pediatric Onset Multiple Sclerosis to Improve Patient Care
source: pixabay.com

Study Shows We Need Better Awareness of Pediatric Onset Multiple Sclerosis to Improve Patient Care

Multiple Sclerosis (MS) was long believed to be an illness that could only affect adults. In fact, the pediatric form of this disease was not discovered until just over 10…

Continue Reading Study Shows We Need Better Awareness of Pediatric Onset Multiple Sclerosis to Improve Patient Care
Scottish Mother Prepares to Obtain Cannabidiol Oil For Her Son With Rare Epilepsy
source: pixabay.com

Scottish Mother Prepares to Obtain Cannabidiol Oil For Her Son With Rare Epilepsy

According to a story from edinburghnews.com, mother Karen Gray is about to seek access to cannabidiol oil for her five-year-old son, Murray, who has a rare type of epilepsy, Myoclonic Astatic…

Continue Reading Scottish Mother Prepares to Obtain Cannabidiol Oil For Her Son With Rare Epilepsy
Delaying Epilepsy Onset in Young Children Could Improve Other Neurological Conditions
1041483 / Pixabay

Delaying Epilepsy Onset in Young Children Could Improve Other Neurological Conditions

Scientists are investigating whether delaying the onset of epilepsy in very young children could reduce or prevent other neurological conditions such as learning difficulties and autism, reports Medical Xpress. This…

Continue Reading Delaying Epilepsy Onset in Young Children Could Improve Other Neurological Conditions
Close Menu